OPHTHETIC
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jan 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPHTHETIC is an ophthalmic solution approved in 1961 for eye-related indications. The specific mechanism of action and therapeutic indication are not publicly detailed in available data, limiting characterization of its clinical role. As a small-molecule eye drop, it represents a foundational therapy in the ophthalmology space.
LOE Approaching
LOE-approaching lifecycle suggests declining revenue and probable team rightsizing; roles will focus on generic transition management and authorized generic strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPHTHETIC offers limited career growth opportunities given its LOE-approaching status and zero linked job postings. Roles focus on protecting remaining revenue, executing generic transition strategy, and supporting AbbVie's ophthalmology portfolio consolidation.
Brand Manager – OphthalmologyField Sales Representative
Worked on OPHTHETIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.